More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Salsalate [552-94-3]
Chemical Structure
Chemical Structure
Chemical Structure

Salsalate [552-94-3]

Research Use Only
AG-CR1-3574
AdipoGen Life Sciences
CAS Number552-94-3
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight258.2
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Salsalate
  • Delivery Days Customer
    10
  • ADR Class
    9
  • CAS Number
    552-94-3
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C14H10O5
  • Molecular Weight
    258.2
  • Scientific Description
    Chemical. CAS: 552-94-3. Formula: C14H10O5. MW: 258.2. Nonacetylated salicylate. Non-steroidal anti-inflammatory drug (NSAID). Reduces pain and inflammation caused by conditions such as rheumatoid arthritis, osteoarthritis and related rheumatic conditions. Prostaglandin synthesis inhibitor in vivo. Inactivates cyclooxygenase-1 (COX-1) and -2 (COX-2). IKKbeta/NF-kappaB inhibitor (at significantly higher concentrations than required for COX inhibition). Used to target inflammation in the treatment of insulin resistance, type 2 diabetes, or rheumatic pain. It reduces blood glucose concentrations in patients with type 2 diabetes, as well as in insulin-resistant patients without diabetes. Reduces blood glucose, triglyceride, free fatty acid and C-reactive protein concentrations, improves glucose utilization and increases circulating insulin and adiponectin concentrations in obese adults at risk for the development of type 2 diabetes as well as for patients with type 2 diabetes. Dimeric prodrug comprising two esterified salicylate moieties. It is advantageous over sodium salicylate because it is insoluble at the acid pH of the stomach and passes suspended but undissolved into the small intestine, sparing the gastric mucosa direct contact. - Nonacetylated salicylate. Non-steroidal anti-inflammatory drug (NSAID). Reduces pain and inflammation caused by conditions such as rheumatoid arthritis, osteoarthritis and related rheumatic conditions. Prostaglandin synthesis inhibitor in vivo. Inactivates cyclooxygenase-1 (COX-1) and -2 (COX-2). IKKbeta/NF-kappaB inhibitor (at significantly higher concentrations than required for COX inhibition). Used to target inflammation in the treatment of insulin resistance, type 2 diabetes, or rheumatic pain. It reduces blood glucose concentrations in patients with type 2 diabetes, as well as in insulin-resistant patients without diabetes. Reduces blood glucose, triglyceride, free fatty acid and C-reactive protein concentrations, improves glucose utilization and increases circulating insulin and adiponectin concentrations in obese adults at risk for the development of type 2 diabetes as well as for patients with type 2 diabetes. Dimeric prodrug comprising two esterified salicylate moieties. It is advantageous over sodium salicylate because it is insoluble at the acid pH of the stomach and passes suspended but undissolved into the small intestine, sparing the gastric mucosa direct contact.
  • SMILES
    OC(=O)C1=CC=CC=C1OC(=O)C1=C(O)C=CC=C1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UN Number
    UN 3077
  • UNSPSC
    12352200

References

  • Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study: S. Roth, et al.; Semin. Arth. Rheum. 19, 11 (1990)
  • Inhibition of NF-kappa B by sodium salicylate and aspirin: E. Kopp & S. Ghosh; Science 265, 956 (1994)
  • Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration: J.W. Pierce, et al.; J. Immunol. 156, 3961 (1996)
  • The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta: M.J. Yin, et al.; Nature 396, 77 (1998)
  • Salsalate improves glycemia and inflammatory parameters in obese young adults: A. Fleischman, et al.; Diabetes Care 31, 289 (2008)
  • Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes: A.B. Goldfine, et al.; Clin. Transl. Sci. 1, 36 (2008)
  • The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study: J. Koska, et al.; Diabetologia 52, 385 (2009)
  • Nuclear factor-kappaB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans: G.L. Pierce, et al.; Circulation 119, 1284 (2009)
  • The effects of salsalate on glycemic control in patients with type 2 diabetes: A randomized trial: A.B. Goldfine, et al.; Ann. Intern. Med. 152, 346 (2010)
  • Potential role of salicylates in type 2 diabetes: M.M. Rumore & K.S. Kim; Ann. Pharmacother. 44, 1207 (2010) (Review)